Doxepin Hydrochloride Capsule
NDC Package 43353-331-16
Package Information
Doxepin Hydrochloride capsules is uSP are recommended for the treatment of:1.Psychoneurotic patients with depression and/or anxiety.2.Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol).3.Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly).4.Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders.The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry.Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. This formulation utilizes a capsule delivery system. Marketed by Aphena Pharma Solutions - Tennessee, Llc, this product is identified by NDC 43353-331 and is authorized under FDA application ANDA070791.
Identification & Billing
- RxCUI: 1000048 - doxepin HCl 10 MG Oral Capsule
- RxCUI: 1000048 - doxepin 10 MG Oral Capsule
- RxCUI: 1000048 - doxepin (as doxepin HCl) 10 MG Oral Capsule
- RxCUI: 1000070 - doxepin HCl 25 MG Oral Capsule
- RxCUI: 1000070 - doxepin 25 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 43353 - Aphena Pharma Solutions - Tennessee, Llc
- 43353-331 - Doxepin Hydrochloride
- 43353-331-16 - 6000 CAPSULE in 1 BOTTLE, PLASTIC
- 43353-331 - Doxepin Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (43353-331). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 43353-331-16 identifies a specific commercial package of 6000 capsule in 1 bottle, plastic of Doxepin Hydrochloride, a human prescription drug labeled by Aphena Pharma Solutions - Tennessee, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 6000 billable units per package. This capsule is formulated for oral use and contains doxepin hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Aphena Pharma Solutions - Tennessee, Llc on May 13, 1986. The current certification is valid through December 31, 2026.
How is this Aphena Pharma Solutions - Tennessee, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 43353033116. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 6000 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.